Similar articles

• CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.

  Linsley PS, Ledbetter J, Peach R, Bajorath J. Linsley PS, et al. Res Immunol. 1995 Mar-Apr;146(3):130-40. doi: 10.1016/0923-2494(96)80246-x. Res Immunol. 1995. PMID: 8525042 Review. No abstract available.
• CTLA-4 and T cell activation.

  Oosterwegel MA, Greenwald RJ, Mandelbrot DA, Lorsbach RB, Sharpe AH. Oosterwegel MA, et al. Curr Opin Immunol. 1999 Jun;11(3):294-300. doi: 10.1016/s0952-7915(99)80047-8. Curr Opin Immunol. 1999. PMID: 10375557 Review.
• The complexities of T-cell co-stimulation: CD28 and beyond.

  Sperling AI, Bluestone JA. Sperling AI, et al. Immunol Rev. 1996 Oct;153:155-82. doi: 10.1111/j.1600-065x.1996.tb00924.x. Immunol Rev. 1996. PMID: 9010723 Review. No abstract available.
• CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?

  van Gool SW, Barcy S, Devos S, Vandenberghe P, Ceuppens JL, Thielemans K, de Boer M. van Gool SW, et al. Res Immunol. 1995 Mar-Apr;146(3):183-96. doi: 10.1016/0923-2494(96)80256-2. Res Immunol. 1995. PMID: 8525052 Review. No abstract available.
• Treatment of autoimmunity by inhibition of T cell costimulation.

  Daikh DI, Wofsy D. Daikh DI, et al. Adv Exp Med Biol. 2001;490:113-7. doi: 10.1007/978-1-4615-1243-1_12. Adv Exp Med Biol. 2001. PMID: 11505969 Review. No abstract available.